Dr. Nipun Verma
@drnipunverma.bsky.social
Clinician Hepatologist dedicated to patient care, teaching and research..
Beautiful lines..
Hot take on hepatic encephalopathy
Is encephalopathy without an elevated ammonia not hepatic at all?
Editorial by ADR and Montagnese: pubmed.ncbi.nlm.nih.gov/40073275/
Original pubmed.ncbi.nlm.nih.gov/39879584/
#liversky
Is encephalopathy without an elevated ammonia not hepatic at all?
Editorial by ADR and Montagnese: pubmed.ncbi.nlm.nih.gov/40073275/
Original pubmed.ncbi.nlm.nih.gov/39879584/
#liversky
March 14, 2025 at 4:18 AM
Beautiful lines..
🚨 New Insights in Cirrhosis! 🚨
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
March 7, 2025 at 4:09 PM
🚨 New Insights in Cirrhosis! 🚨
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
www.journal-of-hepatology.eu/article/S016...
Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social
Reposted by Dr. Nipun Verma
@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go!
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
March 5, 2025 at 3:50 PM
@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go!
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky
Reposted by Dr. Nipun Verma
Systemic inflammation🔥(SI) is a major driver of #liver disease progression in patients with decompensated #cirrhosis.
Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels.
🔗 t.ly/A39-U
Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels.
🔗 t.ly/A39-U
March 6, 2025 at 1:22 PM
Systemic inflammation🔥(SI) is a major driver of #liver disease progression in patients with decompensated #cirrhosis.
Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels.
🔗 t.ly/A39-U
Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels.
🔗 t.ly/A39-U
Reposted by Dr. Nipun Verma
Please delve deeper into “social” drinking with your patients, especially in those with evidence of liver disease. More often than not, drinking that is considered socially acceptable is harmful to the liver. Sometimes a brief intervention/educational moment is enough to save a liver! #liversky
March 5, 2025 at 8:14 PM
Please delve deeper into “social” drinking with your patients, especially in those with evidence of liver disease. More often than not, drinking that is considered socially acceptable is harmful to the liver. Sometimes a brief intervention/educational moment is enough to save a liver! #liversky
Reposted by Dr. Nipun Verma
🆕Article in press❕
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Full text here👉https://bit.ly/4iucrzV
More information here👉https://bwnews.pr/4hadNie
#OpenAccess
#LiverSky
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Full text here👉https://bit.ly/4iucrzV
More information here👉https://bwnews.pr/4hadNie
#OpenAccess
#LiverSky
March 6, 2025 at 3:19 PM
🆕Article in press❕
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Full text here👉https://bit.ly/4iucrzV
More information here👉https://bwnews.pr/4hadNie
#OpenAccess
#LiverSky
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Full text here👉https://bit.ly/4iucrzV
More information here👉https://bwnews.pr/4hadNie
#OpenAccess
#LiverSky
Reposted by Dr. Nipun Verma
Spicy!
Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors
@juancarlosqvelez.bsky.social
doi.org/10.1016/j.ek...
#nephsky #liversky
Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors
@juancarlosqvelez.bsky.social
doi.org/10.1016/j.ek...
#nephsky #liversky
March 4, 2025 at 12:08 AM
Spicy!
Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors
@juancarlosqvelez.bsky.social
doi.org/10.1016/j.ek...
#nephsky #liversky
Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors
@juancarlosqvelez.bsky.social
doi.org/10.1016/j.ek...
#nephsky #liversky
Reposted by Dr. Nipun Verma
Highlighting role of hepatology in the spectrum of HCC care
In this study
Impact of liver decom on clinical outcomes on atezobeva
📌OS better in CP A vs CP B
📌No differences in TTP/safety
📌Liver decomp: 28% CP A vs 51% CP B
📌41% resume after decomp
#Liversky
www.cghjournal.org/article/S154...
In this study
Impact of liver decom on clinical outcomes on atezobeva
📌OS better in CP A vs CP B
📌No differences in TTP/safety
📌Liver decomp: 28% CP A vs 51% CP B
📌41% resume after decomp
#Liversky
www.cghjournal.org/article/S154...
March 3, 2025 at 4:22 PM
Highlighting role of hepatology in the spectrum of HCC care
In this study
Impact of liver decom on clinical outcomes on atezobeva
📌OS better in CP A vs CP B
📌No differences in TTP/safety
📌Liver decomp: 28% CP A vs 51% CP B
📌41% resume after decomp
#Liversky
www.cghjournal.org/article/S154...
In this study
Impact of liver decom on clinical outcomes on atezobeva
📌OS better in CP A vs CP B
📌No differences in TTP/safety
📌Liver decomp: 28% CP A vs 51% CP B
📌41% resume after decomp
#Liversky
www.cghjournal.org/article/S154...
Reposted by Dr. Nipun Verma
🚀 AI & ML are transforming liver disease care!
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer
February 25, 2025 at 4:47 PM
🚀 AI & ML are transforming liver disease care!
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer
🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍
🔗 oaepublish.com/articles/mtod.…#AIA#Liverer
Reposted by Dr. Nipun Verma
🔵 ClustALL paper: This innovative clustering method addresses patient heterogeneity in acutely decompensated #cirrhosis, identifying subgroups with prognostic value to improve trials and personalized care. Read more: translational-medicine.biomedcentral.com/articles/10....
#LiverSky
#LiverSky
A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis - Journal of Translational Medicine
Background Patient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predictin...
translational-medicine.biomedcentral.com
December 19, 2024 at 9:40 AM
🔵 ClustALL paper: This innovative clustering method addresses patient heterogeneity in acutely decompensated #cirrhosis, identifying subgroups with prognostic value to improve trials and personalized care. Read more: translational-medicine.biomedcentral.com/articles/10....
#LiverSky
#LiverSky
Reposted by Dr. Nipun Verma
Reposted by Dr. Nipun Verma
Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial
February 22, 2025 at 2:15 PM
Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial